<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55411">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02011932</url>
  </required_header>
  <id_info>
    <org_study_id>BJYAH-2011-045</org_study_id>
    <nct_id>NCT02011932</nct_id>
  </id_info>
  <brief_title>Prospective Observational Study of Disease Progression in Chronic Hepatitis C</brief_title>
  <official_title>Observational Study of Disease Progression and Risk Factors in Chronic Hepatitis C Caused by Plasma Donation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing YouAn Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing YouAn Hospital</source>
  <oversight_info>
    <authority>China: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the progression of chronic hepatitis C patients
      infected by paid plasma donation,and explore the possible pathogenic mechanisms of disease
      progression in chronic hepatitis C.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">July 2030</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Fibrosis progression rate</measure>
    <time_frame>20 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of cirrhosis</measure>
    <time_frame>20 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk factors for the occurrence of cirrhosis</measure>
    <time_frame>20 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of hepatocellular carcinoma</measure>
    <time_frame>20 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with chronic hepatitis C-related complications</measure>
    <time_frame>20 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">133</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <condition>Disease Progression</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic hepatitis C</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, plasma,liver biopsies specimens,
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The plasma donors were primarily chosen from healthy farmers and agricultural workers
        living in a remote small city in the Northwest China.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All these patients had a definite history of regular plasma donations with repeated
             blood cell re-transfusions.

          -  The Hepatitis C Virus antibody was positive.

          -  All patients did not receive interferon therapy before being recruited.

        Exclusion Criteria:

          -  Patients with evidences for other forms of liver diseases.

          -  The coinfection with hepatitis B virus or other virus.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhongping Duan, Ph.D.,M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing YouAn Hospital, Capital Medical University</affiliation>
  </overall_official>
  <reference>
    <citation>Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S35-46. Review.</citation>
    <PMID>12407575</PMID>
  </reference>
  <reference>
    <citation>Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997 Mar 22;349(9055):825-32.</citation>
    <PMID>9121257</PMID>
  </reference>
  <reference>
    <citation>Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K, Herion D, Park Y, Liang TJ, Hoofnagle JH. Progression of fibrosis in chronic hepatitis C. Gastroenterology. 2003 Jan;124(1):97-104.</citation>
    <PMID>12512034</PMID>
  </reference>
  <reference>
    <citation>Seeff LB, Miller RN, Rabkin CS, Buskell-Bales Z, Straley-Eason KD, Smoak BL, Johnson LD, Lee SR, Kaplan EL. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med. 2000 Jan 18;132(2):105-11.</citation>
    <PMID>10644270</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 13, 2013</lastchanged_date>
  <firstreceived_date>December 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing YouAn Hospital</investigator_affiliation>
    <investigator_full_name>Zhongping Duan</investigator_full_name>
    <investigator_title>Associate Dean,Professor,Chief Physician</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
